Avalyn Pharma Inc. Common Stock
NASDAQ:AVLNMedical - Pharmaceuticals
+$0.52 today
- Market cap
- $1.23B
- Beta
- 0.00
Volume 0.40M
Average 0.51M
AVLN Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Accounts Receivables history
Currency unavailable · from the cash flow
No Accounts Receivables data reported for this period type.
Accounts Receivables vs competitors
How AVLN compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $162.88M USD | +1189.3% | +139.6% | 14.3% | |
| LTM Mar 2026 | $22.62M USD | +351.7% | -26.1% | 6.3% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 8.69M SEK | +561.8% | +24.4% | 653.7% |
| LTM Mar 2026 | $3M USD | -61.4% | +14.7% | 2.6% | |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding AVLN) | — | +456.8% | +19.6% | 10.3% | |
Competitors are the stored peer set for AVLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Avalyn Pharma Inc. Common Stock
NASDAQ:AVLN
Intrinsic Alpha fair value
Locked
Current Price
$27.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.